5552-82-9Relevant academic research and scientific papers
Dual Gold/Silver Catalysis: Indolizines from 2-Substituted Pyridine Derivatives via a Tandem C(sp3)–H Alkynylation/Iminoauration
Han, Chunyu,Liu, Yaowen,Tian, Xianhai,Rominger, Frank,Hashmi, A. Stephen K.
supporting information, p. 9480 - 9484 (2021/12/17)
A dual gold/silver-catalyzed cascade C(sp3)–H alkynylation/iminoauration of 2-substituted pyridines with hypervalent iodine(III) reagents for the synthesis of indolizines is described. This novel reaction involves the formation of an alkynyl Au(III) species, a dual gold/silver-catalyzed C(sp3)–H functionalization, and a subsequent iminoauration process. A number of indolizines bearing diverse functionalities were prepared in good to excellent yield. Furthermore, a gram-scale reaction was efficiently conducted.
Design, Synthesis, and Pharmacological Characterization of a Neutral, Non-Prodrug Thrombin Inhibitor with Good Oral Pharmacokinetics
Hillisch, Alexander,Gericke, Kersten M.,Allerheiligen, Swen,Roehrig, Susanne,Schaefer, Martina,Tersteegen, Adrian,Schulz, Simone,Lienau, Philip,Gnoth, Mark,Puetter, Vera,Hillig, Roman C.,Heitmeier, Stefan
supporting information, p. 12574 - 12594 (2020/11/13)
Despite extensive research on small molecule thrombin inhibitors for oral application in the past decades, only a single double prodrug with very modest oral bioavailability has reached human therapy as a marketed drug. We have undertaken major efforts to identify neutral, non-prodrug inhibitors. Using a holistic analysis of all available internal data, we were able to build computational models and apply these for the selection of a lead series with the highest possibility of achieving oral bioavailability. In our design, we relied on protein structure knowledge to address potency and identified a small window of favorable physicochemical properties to balance absorption and metabolic stability. Protein structure information on the pregnane X receptor helped in overcoming a persistent cytochrome P450 3A4 induction problem. The selected compound series was optimized to a highly potent, neutral, non-prodrug thrombin inhibitor by designing, synthesizing, and testing derivatives. The resulting optimized compound, BAY1217224, has reached first clinical trials, which have confirmed the desired pharmacokinetic properties.
SUBSTITUTED BENZOXAZOLES
-
Paragraph 1579-1580, (2016/05/10)
The invention relates to substituted benzoxazoles and to processes for their preparation and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular of cardiovascular disorders, preferably of thrombotic or thromboembolic disorders.
TRIAZOLOPYRIDINES AS THROMBIN INHIBITORS FOR THE TREATMENT OF THROMBOEMBOLIC DISEASES
-
Paragraph 1566-1567, (2016/05/10)
The invention relates to substituted triazolopyridines and to processes for their preparation and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular of cardiovascular disorders, preferably of thrombotic or thromboembolic disorders.
Triazolopyridines as thrombin inhibitors for the treatment of thromboembolic diseases
-
Paragraph 0443, (2016/10/10)
The invention relates to substituted triazolopyridines and methods for the production thereof, as well as to the use thereof in the production of drugs for treating and/or preventing diseases, especially diseases of the cardiovascular system, preferably thrombotic or thromboembolic diseases.
Substituted benzoxazoles
-
Paragraph 0501, (2016/10/10)
The invention relates to substituted benzoxazoles of formula (1) where R1 stands for a group of formula, and a method for preparing same and their use in the production of drugs for the treatment and/or prevention of diseases, in particular cardiovascular diseases, preferably thrombotic or thromboembolic diseases.
PYRIDAZINE COMPOUND AND USE THEREOF
-
Page/Page column 38, (2008/12/07)
A pyridazine compound of the formula: has an excellent plant disease controlling effect.
Syntheses and structure-activity relationship studies of piperidine-substituted quinolones as nonpeptide gonadotropin releasing hormone antagonists
Jiang, Jinlong,DeVita, Robert J.,Goulet, Mark T.,Wyvratt, Matthew J.,Lo, Jane-L.,Ren, Ning,Yudkovitz, Joel B.,Cui, Jisong,Yang, Yi T.,Cheng, Kang,Rohrer, Susan P.
, p. 1795 - 1798 (2007/10/03)
Syntheses and structure-activity relationships of piperidine-substituted quinolones as nonpeptide gonadotropin releasing hormone antagonists are described. Some of substituents on the piperidine ring that were investigated included a fused phenyl group, a
AZACYCLIC-HETEROCYCLIC COMPOUNDS AS ANGIOTENSION II RECEPTOR ANTAGONISTS
-
, (2008/06/13)
Compounds of the formula STR1 wherein: Q is naphthyl, heterocyclic or heterobicyclic; R 1 and R 2, when taken separately, are hydrogen, hydroxy, alkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, phenyl, heterocyclic or heterobicyclic; R 1 and R 2, when take
Reductive Amination of Ethynylpyridines with Sodium Cyanoborohydride
Sakamoto, Takao,Nagata, Hideo,Kondo, Yoshinori,Sato, Kaori,Yamanaka, Hiroshi
, p. 4866 - 4872 (2007/10/02)
In order to investigate the structure-activity relationship of betahistine derivatives, a general synthesis of methylated 2-(2-methylaminoethyl)pyridines was developed based on the addition of methylamine hydrochloride to methylated 2-ethynylpyridines under reductive conditions.In addition, the scope and limitations of the reductive addition were briefly examined.For example, the reaction proceeded smoothly with p-nitrophenylacetylene, whereas phenylacetylene itself did not react with methylamine.Keywords - ethynylpyridine; sodium cyanoborohydride; reductive amination; betahistine; palladium-catalyzed reaction; ethyl pyridineacetate; 2-(2-pyridyl)ethylamine
